Nov 8, 2019 Targeting Multiple Immune Checkpoint Proteins With Novel Small Molecular Inhibitors of Sec61-dependent Cotranslational Translocation Kezar Life Sciences, Inc
Nov 5, 2019 The Pharmacokinetic Differences Between Humans and Animals of KZR-616, a First-In-Class, Selective Immunoproteasome Inhibitor, In Two Clinical Formulations Kezar Life Sciences, Inc
Jun 13, 2019 Treatment of Systemic Lupus Erythematosus Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 2 Cohorts of an Open-label Phase 1b Dose Escalation Trial Kezar Life Sciences, Inc
Apr 10, 2019 Proteomic Profiling of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61 Kezar Life Sciences, Inc.
Apr 6, 2019 KZR-616, A Selective Inhibitor of the Immunoproteasome, Attenuates the Development of Murine Lupus Nephritis Kezar Life Sciences, Inc.
Apr 2, 2019 KZR-8834: A Novel, Small Molecule Inhibitor of Sec61-Dependent Protein Secretion with Anti-Tumor Activity Kezar Life Sciences, Inc.
Apr 2, 2019 Discovery and Characterization of Novel Anti-Cancer Small Molecule Inhibitors of Sec61 Kezar Life Sciences, Inc.
Nov 6, 2018 Pharmacokinetics, Pharmacodynamics, and Their Relationship of KZR-616 in Healthy Volunteers Kezar Life Sciences, Inc.
Nov 5, 2018 Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome Kezar Life Sciences, Inc.
Oct 31, 2018 Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 Journal of Medicinal Chemistry
